Sunday, 27 December 2015 11:12

Anticoagulation news items. Weeks commencing 21st December 2015

What doses of thromboprophylaxis are appropriate for adult patients at extremes of body weight?


This updated Medicines Q&A prepared by the Haemostasis Anticoagulation and Thrombosis Committee of the UK Clinical Pharmacy Association reviews the data available and offers guidance on dosing of thromboprophylaxis in patients who are obese or of low body weight.


Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom

European Heart Journal

Analysis of UK national PCI registry (n=61,138 procedures) noted no significant difference in short- or medium-term mortality between ST elevation myocardial infarction patients treated with bivalirudin vs. heparin-plus-glycoprotein inhibitors at primary PCI.


Time to Reperfusion and Treatment Effect for Acute Ischemic Stroke A Randomized Clinical Trial

JAMA Neurology

RCT (n=500) found that for every hour of reperfusion delay, the initially large benefit of intra-arterial treatment decreases, with the absolute risk
difference for a good outcome being reduced by 6% per hour of delay.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: